Table 1.
Patient characteristics at baseline, overall and by region.
| Characteristics | Overall (n = 20,364; 100%) | Western Europe (n = 13,715; 67.3%) | Central-Eastern Europe (n = 3020; 14.8%) | Eastern Europe (n = 3629; 17.8%) | p-value |
|---|---|---|---|---|---|
| Median baseline date | 2004-01-16 | 2008-07-10 | 2008-12-11 | ||
| Median age (IQR) | 40 (33–48) | 42 (36–50) | 35 (30–43) | 32 (27–39) | <0.001 |
| Years since HIV diagnosis | 8.6 (3.9–14.9) | 11.2 (6.4–16.5) | 3.6 (1.5–6.5) | 3.2 (1.3–6.1) | <0.001 |
| Gender | |||||
| Male | 14,993 (73.7%) | 10,575 (77.1%) | 2326 (77%) | 2102 (57.9%) | <0.001 |
| HIV transmission risk | |||||
| MSM | 7529 (37%) | 5967 (43.5%) | 1334 (44.2%) | 228 (6.3%) | <0.001 |
| Injection Drug Use | 5817 (28.6%) | 3300 (24.1%) | 774 (25.6%) | 1755 (48.4%) | |
| Heterosexual Contact | 5661 (27.8%) | 3450 (25.2%) | 698 (23.1%) | 1514 (41.7%) | |
| Other/unknown | 1344 (6.6%) | 998 (7.3%) | 214 (7.1%) | 132 (3.6%) | |
| ART status | |||||
| On ART | 16,584 (81.5%) | 12,060 (87.9%) | 2550 (84.4%) | 1978 (54.5%) | <0.001 |
| Off ART, not naïve | 874 (4.3%) | 672 (4.9%) | 69 (2.3%) | 133 (3.7%) | |
| ART naïve | 2893 (14.2%) | 983 (7.2%) | 401 (13.3%) | 1518 (41.8%) | |
| CD4-cell count (cells/mm3) | |||||
| Median | 449 (291–638) | 461 (301–657) | 433 (280–620) | 409 (259–588) | <0.001 |
| CD4 < 200 | 2463 (12.1%) | 1533 (11.2%) | 396 (13.1%) | 534 (14.7%) | <0.001 |
| HIV RNA Viral Load (cp/mL) | |||||
| Median | 49 (39–1718.8) | 49 (31–890) | 49 (39–751) | 499 (74–21300) | <0.001 |
| Immunologic-virologic status | |||||
| Poor (CD4 ≤ 350 & VL > 200) | 2781 (13.7%) | 1783 (13%) | 383 (12.7%) | 615 (16.9%) | <0.001 |
| Intermediate | 8988 (44.2%) | 6307 (46%) | 1409 (46.7%) | 1273 (35.1%) | |
| Good (CD4 ≥ 500 & VL < 200) | 5932 (29.1%) | 4593 (33.5%) | 860 (28.5%) | 479 (13.2%) | |
| Unknown | 2650 (13%) | 1032 (7.5%) | 368 (12.2%) | 1262 (34.8%) | |
| AIDS history | 5069 (24.9%) | 3768 (27.5%) | 662 (21.9%) | 645 (17.8%) | <0.001 |
| CVD history | 403 (2%) | 365 (2.7%) | 29 (1%) | 9 (0.2%) | <0.001 |
| Diabetes history | 682 (3.4%) | 597 (4.4%) | 71 (2.4%) | 14 (0.4%) | <0.001 |
| ESRD history | 44 (0.2%) | 39 (0.3%) | 5 (0.2%) | 0 (0%) | 0.004 |
| ESLD history | 168 (1.2%) | 168 (1.2%) | 7 (0.2%) | 22 (0.6%) | <0.001 |
| NADM history | 400 (2%) | 362 (2.6%) | 23 (0.8%) | 15 (0.4%) | <0.001 |
| Smoking history | |||||
| Never | 4229 (20.8%) | 2657 (19.4%) | 881 (29.2%) | 691 (19%) | <0.001 |
| Former | 8206 (40.3%) | 5960 (43.5%) | 1081 (35.8%) | 1170 (32.2%) | |
| Current | 3873 (19%) | 1955 (14.3%) | 722 (23.9%) | 1204 (33.2%) | |
| Unknown | 4043 (19.9%) | 3143 (22.9%) | 336 (11.1%) | 564 (15.5%) | |
| TB history | |||||
| Never TB | 19,247 (94.6%) | 13,008 (94.9%) | 2858 (94.7%) | 3392 (93.5%) | <0.001 |
| TB pre-baseline | 1104 (5.4%) | 707 (5.1%) | 162 (5.3%) | 237 (6.5%) | |
| Hepatitis C Virus (HCV) | |||||
| Ever HCV antibody positive at baseline | 8105 (39.8%) | 4875 (35.5%) | 1040 (34.4%) | 2200 (60.6%) | <0.001 |
IQR–Interquartile range; MSM–Men having sex with men; ART-Antiretroviral therapy; AIDS–acquired immunodeficiency syndrome; CVD–cardiovascular disease; ESRD-End stage renal disease; NADM–Non-AIDS defining malignancies; TB-tuberculosis; VL-HIV-RNA viral load, VL-HIV-RNA values that are below the lower limit of detection (LOD) are given a value of (LOD-1).